ClearRead CT CAC

Riverain Technologies' ClearRead CT CAC device is an image processing software designed to automatically assess coronary artery calcification (CAC) from standard or low-dose chest CT scans, providing Agatston scores and CAC categories to aid physicians in patient risk evaluation. Its efficacy and safety were rigorously validated through non-clinical and clinical studies, demonstrating substantial equivalence and high agreement with manual methods using metrics like kappa scores and Bland-Altman analysis for accurate, automated quantification of CAC.

Riverain Technologies, Inc.'s ClearRead CT CAC device, an image processing software, has received regulatory clearance for assessing coronary artery calcification (CAC) on non-gated, non-contrast, standard, or low-dose chest CT scans in adults aged 30 or older. This device's primary function is to generate an Agatston score, which subsequently determines a CAC category and arterial age, thereby assisting physicians in cardiovascular risk assessment. Its clearance was based on its demonstrated substantial equivalence to existing legally marketed predicate devices, affirming its intended use under general regulatory controls. The device's efficacy and safety were rigorously supported by extensive non-clinical and clinical performance testing. Non-clinical evaluations, involving approximately 400 cases, confirmed compliance with quality standards and showed high agreement (weighted kappa of 0.958) between automated and manual CAC categorization. A clinical study with 491 non-contrast chest CT cases further validated its accuracy, achieving a primary endpoint kappa score of 0.959 for Agatston score category agreement and demonstrating robust consistency for continuous scores and segmentation through Bland-Altman and Dice score analyses. These comprehensive results collectively establish the device's reliability for its specified diagnostic purpose.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the ClearRead CT CAC device perform compared to traditional manual scoring methods in terms of physician workflow efficiency and diagnostic turnaround time?; What are the specific limitations or contraindications for using the ClearRead CT CAC device, particularly regarding image quality artifacts or patient populations not covered by the study?; Could the device's output, specifically the derived arterial age, influence patient management decisions or risk stratification in a clinical setting beyond the Agatston score?; Are there ongoing studies or plans to expand the device's utility to other imaging modalities or to integrate it into broader cardiovascular risk assessment platforms?; How might the use of low-dose CT scans, as supported by the device, impact long-term patient exposure to radiation and the generalizability of the Agatston score accuracy?